News
Resources
Blog
Sites
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications, national advocacy events and grassroots initiative, Voters for Cures. He also helped found and currently co-chairs The PRIDE Umbrella, PhRMA’s employee resource group for LGBTQ+ colleagues. Before joining PhRMA in 2015, Andrew worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; and served on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists, singer with The Gay Men’s Chorus of Washington, and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.
Recent Posts
Novel medicines approved in 2022 offer increased treatment options for patients
By Andrew Powaleny | January 23, 2023
2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...
Read More
What they are saying: PASTEUR Act can help fight antimicrobial resistance
By Andrew Powaleny | November 30, 2022
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and 1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and...
Read More
Mental Illness Awareness Week – A time for reflection
By Andrew Powaleny | October 3, 2022
Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or...
Read More
Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines
By Andrew Powaleny | September 12, 2022
As we’ve discussed on this blog before, timely reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug...
Read More
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
By Andrew Powaleny | August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...
Read More
The Patient Perspective: Government price-setting harms patients
By Andrew Powaleny | July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...
Read More
ICYMI: Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
By Andrew Powaleny | July 14, 2022
A new report released by the U.S. Centers for Disease Control and Prevention (CDC) shows the number of antimicrobial-resistant (AMR) infections rose dramatically during the first year of the COVID-19...
Read More
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
By Andrew Powaleny | July 6, 2022
On June 28, PhRMA Chief Operating Officer Lori Reilly joined Executive Director of CARB-X, Kevin Outterson, Esq., and Interim Secretariat Lead of the Global Antimicrobial Resistance (AMR) R&D Hub,...
Read More
Recognizing LGBTQ+ Pride in biopharmaceutical science
By Andrew Powaleny | June 9, 2022
June is Pride Month and, like many across the country, we look forward to celebrating the importance of equality and reminding ourselves to continually seek opportunities to make our society more...
Read More
Report: More than 500 medicines in development to treat disorders of the blood
By Andrew Powaleny | May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
